This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Arcturus Therapeutics (ARCT) Surges 7.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -55.26% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -46.43% and -90.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -4.02% and -27.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcturus Therapeutics (ARCT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -85.34% and -27.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA
by Zacks Equity Research
The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.
Earnings Preview: Arcturus Therapeutics (ARCT) Q4 Earnings Expected to Decline
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Arcturus (ARCT) This Earnings Season?
by Zacks Equity Research
Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.
Beat Your Portfolio Fatigue by Dumping These Toxic Stocks
by Rimmi Singhi
Stocks without sturdy fundamentals are toxic for your portfolio. Identifying such bloated stocks accurately and dumping them at the right time can protect your returns.
Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.
7 Nasdaq ETFs to Play the Index's Winning Momentum
by Sanghamitra Saha
The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.
Nasdaq Hits 13,000 for the First Time: ETFs to Bet On
by Sanghamitra Saha
The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.
Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.
Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study
by Zacks Equity Research
Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
by Zacks Equity Research
Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results
by Zacks Equity Research
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
by Kinjel Shah
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -95.74% and -26.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?